ArticleViruses2026
Extended Duration of Anti-HEV IgM Seropositivity in Asymptomatic Blood Donors: Implications for Transfusion Safety.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Infection with Hepatitis E Virus (HEV) is often asymptomatic but can also lead to chronic infection in immunosuppressed individuals. Although fecal-oral transmission of HEV is well established, transmission by blood transfusion has also been reported. Here, we studied HEV seroprevalence in a cohort of 1000 blood donors (50% male, age 18-73 years, mean 35 years) at the University Medical Center Hamburg-Eppendorf in Germany. We found a seroprevalence of anti-HEV IgG of 16.6%. Interestingly, 1.3% of the blood donors had positive IgM serology despite testing negative for HEV by polymerase chain reaction (PCR). Analysis of preceding and follow-up samples showed persistence of IgM antibodies for up to seven months in asymptomatic individuals. In eight individuals, anti-HEV IgM positivity persisted for 0 to 7 months (median 2 months), as confirmed by testing stored samples. This study demonstrates that anti-HEV IgM positivity can persist for more than six months in individuals who had neither clinically overt hepatitis E nor a viremia duration that would allow PCR positivity to be detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.